000			01924nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aRadiopharmaceuticals for PET Imaging - Issue A
546			_aEnglish[eng]
650			_akinetic analysis||Siglec-9||gallium-68||vascular adhesion protein||VAP-1||infection||inflammation||osteomyelitis||animal model||Staphylococcus aureus||multiple myeloma||positron emission tomography/computed tomography||radiopharmaceuticals||18F-fluorodeoxyglucose||tetrazine ligation||PET||SPECT||indium-11||fluorine-18||positron emission tomography (PET), defluorination||isotopic exchange||silicon-based fluoride acceptor||bioorthogonal chemistry||tetrazine||inverse electron-demand Diels-Alder ligation||opioid||naloxone||overdose||fentanyl||carfentanil||[11C]carfentanil||positron emission tomography||receptor occupancy||pharmacokinetics||[18F]AlF||NOTA||NODAGA||PODS||thiol-reactive||linker||affibody molecule||bioconjugation||EGFR||tumor imaging||vulnerable plaque||molecular imaging||PET imaging||nanobody||single-domain antibody||sub-millimetre resolution||AlF-radiolabelling||preclinical radiopharmaceutical dosimetry||image-based internal dosimetry||OLINDA||MCT1/MCT4 lactate transporter inhibitor||[18F]FACH||radiation safety||sigma-1 receptor availability||orthotopic xenograft of glioblastoma in mouse||small animal Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI)||(S)-(−)-[18F]fluspidine||imaging-based biomarker||SV2A protein||PET radiotracers||synaptic loss||radiochemistry||preclinical development||clinical outcomes||monocarboxylate transporters (MCTs)||FACH||18F-labeled analog of FACH||α-CCA||blood-brain barrier (BBB)||positron emission tomography (PET) imaging||peptides||proteolysis||metabolic stability
700			_aRoivainen, Anne||Li, Xiang-Guo
856			_uhttps://mdpi.com/books/pdfview/book/3155
942			_cEB
999			_c26609 _d26609